Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease
Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease
复制标题
DOI：
10.6004/jnccn.2010.0033
复制
发表时间：
2010-04-01
影响因子：
13.4
通讯作者：
Kelsen, David P.
中科院分区：
文献类型：
--
作者：
Shah, Manish A.;Kelsen, David P.
胃癌是世界范围内发病率和癌症相关死亡率很高的一个原因。尽管最近在靶向治疗和恶性肿瘤的生物学和发展的理解方面取得了进展，但胃癌治疗的进展仍然有限。大多数新诊断的患者将出现无法治愈的疾病，中位生存期不到1年。虽然胃癌有广泛的种族和流行病学差异，但胃癌的医疗管理并不区分各种疾病亚型。ToGA III期研究的最新报告证实了Her 2作为这种疾病的分子靶点，支持了更好地了解胃癌亚群生物学可能改善治疗选择和个体患者总体结局的概念。本文总结了这种疾病的流行病学和种族差异，以明确胃癌的亚型，在当前和未来的医疗管理的先进疾病。（JNCCN 2010;8：437-447）
Gastric cancer is a cause of significant morbidity and cancer-related mortality worldwide. Despite recent advances in targeted therapy and understanding of the biology and development of the malignancy, progress in the treatment of gastric cancer has been limited. Most newly diagnosed patients will present with incurable disease, and have a median survival of less than 1 year. Although the disease has widespread ethnic and epidemiologic differences, medical management of gastric cancer does not distinguish among the various disease subtypes. The recent report of the ToGA phase III study has validated Her2 as a molecular target in this disease, supporting the concept that a greater understanding of the biology of gastric cancer subsets may improve treatment selection and overall outcome of individual patients. This article summarizes the epidemiology and ethnic variation of this disease to crystalize subtypes of gastric cancer in the context of current and future medical management of advanced disease. (JNCCN 2010;8:437-447)